[
  {
    "ts": "2025-12-03T06:57:36+00:00",
    "headline": "Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly & Company (NYSE:LLY) reached another milestone on November 21, becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse. The company’s stock has rallied more […]",
    "url": "https://finance.yahoo.com/news/bernstein-reaffirms-price-target-eli-065736847.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "fa1cfcb7-4332-376e-87d6-cbbfc643ae18",
      "content": {
        "id": "fa1cfcb7-4332-376e-87d6-cbbfc643ae18",
        "contentType": "STORY",
        "title": "Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains",
        "description": "",
        "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly & Company (NYSE:LLY) reached another milestone on November 21, becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse. The company’s stock has rallied more […]",
        "pubDate": "2025-12-03T06:57:36Z",
        "displayTime": "2025-12-03T06:57:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23",
          "originalWidth": 283,
          "originalHeight": 178,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8PhkuSOImzcJWO03ORbAAA--~B/aD0xNzg7dz0yODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23.cf.webp",
              "width": 283,
              "height": 178,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LIJLTrtCu6kOCCm8Vfx83Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bernstein-reaffirms-price-target-eli-065736847.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bernstein-reaffirms-price-target-eli-065736847.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T11:45:00+00:00",
    "headline": "2 Trillion-Dollar Dividend Stocks to Buy and Hold for 10 Years",
    "summary": "They are capitalizing on their ability to innovate and rewarding loyal shareholders in the process.",
    "url": "https://www.fool.com/investing/2025/12/03/2-trillion-dollar-dividend-stocks-to-buy-and-hold/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "93634ef9-9732-34d8-ab9b-ad71c5aa3bb1",
      "content": {
        "id": "93634ef9-9732-34d8-ab9b-ad71c5aa3bb1",
        "contentType": "STORY",
        "title": "2 Trillion-Dollar Dividend Stocks to Buy and Hold for 10 Years",
        "description": "",
        "summary": "They are capitalizing on their ability to innovate and rewarding loyal shareholders in the process.",
        "pubDate": "2025-12-03T11:45:00Z",
        "displayTime": "2025-12-03T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/d4bb41254bcdf706dd76eb0f59c776a6",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Person working at a desk.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZnt6YqA8Mddfw2B2b3Rlw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/d4bb41254bcdf706dd76eb0f59c776a6.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/23oGP.5PHNDBFlQJBGfLpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/d4bb41254bcdf706dd76eb0f59c776a6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/03/2-trillion-dollar-dividend-stocks-to-buy-and-hold/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-trillion-dollar-dividend-stocks-114500416.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T13:00:00+00:00",
    "headline": "Excelsior Sciences Raises $95 Million to Transform Small Molecule Discovery and Manufacturing with Novel Chemistry that Machines Can Do",
    "summary": "NEW YORK, December 03, 2025--Excelsior Sciences, a company developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery, today announced it has raised $95 million to accelerate its mission to reinvent the process of discovering and manufacturing small molecules.",
    "url": "https://finance.yahoo.com/news/excelsior-sciences-raises-95-million-130000531.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "c84f2c50-37fa-3dd2-bc51-cafebd3f88c0",
      "content": {
        "id": "c84f2c50-37fa-3dd2-bc51-cafebd3f88c0",
        "contentType": "STORY",
        "title": "Excelsior Sciences Raises $95 Million to Transform Small Molecule Discovery and Manufacturing with Novel Chemistry that Machines Can Do",
        "description": "",
        "summary": "NEW YORK, December 03, 2025--Excelsior Sciences, a company developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery, today announced it has raised $95 million to accelerate its mission to reinvent the process of discovering and manufacturing small molecules.",
        "pubDate": "2025-12-03T13:00:00Z",
        "displayTime": "2025-12-03T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/71c3f76a3c7e464e84f73b1171c409f9",
          "originalWidth": 480,
          "originalHeight": 240,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nN8f9cakDk_Ma4urIkuT2A--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/71c3f76a3c7e464e84f73b1171c409f9.cf.webp",
              "width": 480,
              "height": 240,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s3iXb5QUUIyoC_xFkZJyHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/71c3f76a3c7e464e84f73b1171c409f9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/excelsior-sciences-raises-95-million-130000531.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/excelsior-sciences-raises-95-million-130000531.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T12:26:21+00:00",
    "headline": "Tech Is Getting Left Behind in the S&P 500’s Latest Rebound",
    "summary": "Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record.  In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp.  The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.",
    "url": "https://finance.yahoo.com/news/tech-getting-left-behind-p-122621068.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "6d27d5f9-23ad-31b3-8a2a-573527e1ad07",
      "content": {
        "id": "6d27d5f9-23ad-31b3-8a2a-573527e1ad07",
        "contentType": "STORY",
        "title": "Tech Is Getting Left Behind in the S&P 500’s Latest Rebound",
        "description": "",
        "summary": "Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record.  In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp.  The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.",
        "pubDate": "2025-12-03T12:26:21Z",
        "displayTime": "2025-12-03T12:26:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/9d9c9990ef4ac9f3e53c8a0efb7119e2",
          "originalWidth": 2000,
          "originalHeight": 1333,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SAl48l8fQmleVEUvq9UUMA--~B/aD0xMzMzO3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/9d9c9990ef4ac9f3e53c8a0efb7119e2.cf.webp",
              "width": 2000,
              "height": 1333,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_FGrfUbJWYGnMHq.oDNFqg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/9d9c9990ef4ac9f3e53c8a0efb7119e2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tech-getting-left-behind-p-122621068.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tech-getting-left-behind-p-122621068.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "CAH"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T14:26:00+00:00",
    "headline": "Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?",
    "summary": "Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.",
    "url": "https://finance.yahoo.com/news/lly-strengthen-lead-glp-1-142600653.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a12adde5-bec3-3c31-8c39-1530d2fdf49a",
      "content": {
        "id": "a12adde5-bec3-3c31-8c39-1530d2fdf49a",
        "contentType": "STORY",
        "title": "Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?",
        "description": "",
        "summary": "Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.",
        "pubDate": "2025-12-03T14:26:00Z",
        "displayTime": "2025-12-03T14:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lly-strengthen-lead-glp-1-142600653.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lly-strengthen-lead-glp-1-142600653.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T18:10:00+00:00",
    "headline": "1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year",
    "summary": "A key catalyst may be right around the corner.",
    "url": "https://www.fool.com/investing/2025/12/03/1-reason-to-buy-eli-lilly-hand-over-fist/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f6b6454b-09e8-32da-9f3d-eb5429ff0901",
      "content": {
        "id": "f6b6454b-09e8-32da-9f3d-eb5429ff0901",
        "contentType": "STORY",
        "title": "1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year",
        "description": "",
        "summary": "A key catalyst may be right around the corner.",
        "pubDate": "2025-12-03T18:10:00Z",
        "displayTime": "2025-12-03T18:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/908fd7d8e216d76bd4a5967cb798dbc4",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Two investors, in a living room decorated for the holidays, look at something on a laptop.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yxtFawNo5oMoTosjnkAoMw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/908fd7d8e216d76bd4a5967cb798dbc4.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wfej1TwmqgRXDnKyVwZiWQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/908fd7d8e216d76bd4a5967cb798dbc4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/03/1-reason-to-buy-eli-lilly-hand-over-fist/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-reason-buy-eli-lilly-181000151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T17:59:00+00:00",
    "headline": "U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts",
    "url": "https://finance.yahoo.com/news/u-fda-approves-expanded-indication-175900379.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b41874c1-e67f-33d5-b78e-efbcb6801faa",
      "content": {
        "id": "b41874c1-e67f-33d5-b78e-efbcb6801faa",
        "contentType": "STORY",
        "title": "U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts",
        "pubDate": "2025-12-03T17:59:00Z",
        "displayTime": "2025-12-03T17:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-fda-approves-expanded-indication-175900379.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-fda-approves-expanded-indication-175900379.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]